Organon Pharmaceuticals Usa Inc.
Organon Pharmaceuticals USA Inc., a prominent player in the global healthcare landscape, is headquartered in the United States. Founded in 2021, the company emerged as a spin-off from Merck & Co., focusing on women's health, biosimilars, and other therapeutic areas. With a commitment to advancing healthcare solutions, Organon offers a diverse portfolio of products, including contraceptives and hormone therapies, distinguished by their innovative formulations and patient-centric approach. Operating primarily in North America and expanding into international markets, Organon has quickly established itself as a leader in women's health. The company’s dedication to addressing unmet medical needs has garnered recognition, positioning it as a trusted partner in the pharmaceutical industry. With a strong emphasis on research and development, Organon continues to make significant strides in improving health outcomes for women worldwide.
DitchCarbon Score
How does Organon Pharmaceuticals Usa Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Organon Pharmaceuticals Usa Inc.'s score of 42 is higher than 76% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Organon Pharmaceuticals Usa Inc.'s reported carbon emissions
Organon Pharmaceuticals USA Inc. currently does not have available data on carbon emissions, as no specific emissions figures have been provided. Consequently, there are no reported Scope 1, 2, or 3 emissions data to analyse. Additionally, the company has not outlined any formal reduction targets or climate pledges, which limits the ability to assess their commitments towards climate action. In the context of the pharmaceutical industry, many companies are increasingly focusing on sustainability and reducing their carbon footprints. However, without specific commitments or data from Organon Pharmaceuticals, it is challenging to evaluate their position in this regard. As the industry moves towards greater transparency and accountability in emissions reporting, it will be important for Organon to establish clear climate commitments and reduction strategies in the future.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Organon Pharmaceuticals Usa Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
